Prognostic Factors for Survival in Adult Patients With Grade II Glial Tumors

Yükleniyor...
Küçük Resim

Tarih

2018

Dergi Başlığı

Dergi ISSN

Cilt Başlığı

Yayıncı

Erişim Hakkı

info:eu-repo/semantics/openAccess

Özet

Aim: To investigate survival results of patients with low grade gliomas (LGGs) and to evaluate the predictive role of clinico-pathologic prognostic factors on survival.Material and Methods: Between 2003 and 2014, the adult patients with Grade II glial tumors were evaluated retrospectively. Several variables were investigated to find prognostic factors related with the overall survival (OS) and progression-free survival (PFS).Results: This study involved in 124 patients with median 40 months follow up. The average OS for the all patients was 7.8 years. 2-, 5- and 10- year OS ratios were 91%, 73% and 55%, respectively. Patients with low pignatti risk score had a longer OS than high pignatti risk score (p0.01). Patients with seizure had a better OS (p0.03). Patients with biopsy/partial resection had a poorer OS (p0.02). Patients with residue after initial surgery had a worse OS (p0.03). If the patients had recurrence or progression, the patients had poorer OS (p0.01). Tumor with malignant transformation (p0.01) and glioblastoma subtype after second surgery (p0.003) had a poorer OS. The Pignatti risk score and seizure were the independent prognostic factors for PFS.Conclusion: The extent of surgery and recurrence or progression of Grade II glioma were the independent prognostic factors for OS. The Pignatti risk score and seizure were the independent prognostic factors for PFS.

Açıklama

Anahtar Kelimeler

Genel ve Dahili Tıp, Grade II Glioma, Prognostic Factors, Progression Or Recurrence Free Survival, Radiotherapy, Survival

Kaynak

Turgut Özal Tıp Merkezi Dergisi

WoS Q Değeri

Scopus Q Değeri

Cilt

25

Sayı

1

Künye

Önder, H., Kanyılmaz, G., Aktan, M., Karahacıoğlu, E. (2018). Prognostic factors for survival in adult patients with grade II glial tumors. Journal of Turgut Ozal Medical Center, 25, 1, 105-111.